MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from the sale andmaturity of marketable...$48,782K Proceeds from exercise ofstock options$4,729K Net cash provided byinvesting activities$21,549K Net cash provided byfinancing activities$4,204K Canceled cashflow$27,233K Canceled cashflow$525K Net (decrease)increase in cash and cash...-$14,673K Canceled cashflow$25,753K Depreciation andamortization$25,212K Share basedcompensation$16,146K Other current andnon-current liabilities$1,940K Purchase of intangibleassets$22,178K Purchase of marketabledebt securities$5,055K Payment of guaranteedminimum royalty$525K Net cash used inoperating activities-$40,366K Canceled cashflow$43,298K Effect of exchange ratechanges on cash-$60K Net loss fromcontinuing operations-$36,602K Accrued expenses-$20,900K Accounts payable-$11,809K Accounts receivable$7,225K Prepaid expenses andother current and...$6,382K Inventory$742K Other$4K
Cash Flow
source: myfinsight.com

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics, Inc. (TVTX)